Lamivudine/tenofovir
 |
 | |
| Combination of | |
|---|---|
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Cimduo, Temixys |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618039 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][3] It contains lamivudine and tenofovir disoproxil.[1] It is taken by mouth.[1]
Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]
References
[edit]- ^ a b c d e "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.
- ^ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.
- ^ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
- ^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
Further reading
[edit]- "WHO Public Assessment Report: HA414 - Lamivudine/Tenofovir disoproxil fumarate - 300mg/300mg - Tablets - Mylan Laboratories Ltd - India". World Health Organization (WHO). Archived from the original on 26 March 2020.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |